The goal of this study is to investigate that a common cholesterol lowering agent
(atorvastatin) alone or combining with a nonsteroidal anti-inflammatory drug (aspirin) would
reduce the risk of colorectal cancer (CRC) in high-risk individuals with Lynch syndrome.